Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.

Condreay, L D; Jansen, R W; Powdrill, T F; Johnson, L C; Selleseth, D W; Paff, M T; Daluge, S M; Painter, G R; Furman, P A; Ellis, M N

Condreay, L D; Jansen, R W; Powdrill, T F; Johnson, L C; Selleseth, D W; Paff, M T; Daluge, S M; Painter, G R; Furman, P A; Ellis, M N.

Affiliation

Condreay LD; Division of Experimental Therapy, Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.

Antimicrob Agents Chemother ; 38(3): 616-9, 1994 Mar.

Article in En | MEDLINE | ID: mdl-7515609

Subject(s)

Antiviral Agents/therapeutic use; Hepatitis B/drug therapy; Zalcitabine/analogs & derivatives; Animals; Biological Availability; Cell Line; DNA, Viral/biosynthesis; Emtricitabine/analogs & derivatives; Hepatitis B/microbiology; Hepatitis B virus/drug effects; Humans; Mice; Polymerase Chain Reaction; Virus Replication/drug effects; Zalcitabine/therapeutic use; alpha-Fetoproteins/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Zalcitabine / Hepatitis B Limits: Animals / Humans Language: En Journal: Antimicrob Agents Chemother Year: 1994 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google